Ageing society will have ‘serious consequences’ for young people, government warned

A House of Lords committee warns the UK is unprepared for a rapidly ageing population, noting those aged 65+ rose to 18.9% of the population in 2023 (from 16.5% in 2011 and 13% in 1972) and citing OBR projections that this could exceed 27% by 2074. Falling fertility (1.44 children per woman in England and Wales, 2023) and ageing pressure on pensions, social care and health spending underpin an OBR scenario in which borrowing could exceed 20% and public debt approach ~270% of GDP by 2070; the report criticises reliance on raising the state pension age and urges policies to keep older workers employed while the government points to planned adult social care reforms and employment measures.

Analysis

Market structure: The UK’s ageing trend (65+ 18.9% in 2023 → OBR 27% by 2074) structurally reroutes demand toward healthcare, primary-care real estate and social-care staffing while shrinking school-age cohorts and some consumer categories. Private care providers, medical device and pharma companies with ageing-market exposure gain pricing power; school operators, entry-level consumer discretionary and some housebuilders face demand compression. Fiscal stress (OBR: borrowing >20%, debt ~270% of GDP by 2070) also biases markets toward higher long-term gilt yields and weaker sterling over decades.

Risk assessment: Tail risks include abrupt policy shifts (nationalisation of social care or VAT/pension tax hikes) or a sovereign downgrade that spikes 10Y gilts by >200bps in a shock. Immediate (days) impact is muted; short-term (0–12 months) risks concentrate around Budgets and OBR updates; long-term (5–25 years) exposures play through demographics and productivity. Hidden dependencies: migration policy, automation/telehealth adoption, and private pension behaviour can materially offset fiscal strain.

Trade implications: Favor long positions in UK-listed healthcare/pharma (e.g., AZN, GSK) and primary-care property REITs (ASR) while hedging duration risk via short 30Y gilt futures or buying long-dated gilt put spreads. Rotate out of UK domestic cyclicals (housebuilders PSN, TW) and education services; consider short GBPUSD via puts (6–18 month expiries) targeting 5–10% depreciation if fiscal signals worsen.

Contrarian angles: Consensus assumes inexorable pension-age lifts and dire sovereign outcomes; markets may underprice offsetting levers — immigration relaxation, productivity gains from health-tech and robotics — which would benefit selected UK equities (medtech, staffing). Conversely, healthcare equities may be crowded; look for mispricings where valuation premium exceeds 20–30% vs peers and use relative-value pairs to express views.

Key Decisions for Investors

• Establish a 2–3% long position in AstraZeneca (AZN) and 1–2% in GlaxoSmithKline (GSK) across global listings, holding 12–36 months to capture ageing-driven volume and pricing tailwinds; size depends on portfolio risk tolerance.
• Initiate a 2% long in Assura plc (ASR.L) or similar UK primary-care property REITs to play rising demand for GP/retirement-facing facilities; hedge with a 0.5–1% short in Persimmon (PSN.L) or Taylor Wimpey (TW.L) to express weaker new-family housing demand over 12–24 months.
• Short UK interest-rate duration: enter a position short 30Y gilt futures equal to 1–2% portfolio DV01 or buy a 1-year put spread on long-dated gilts to protect against a >100bps move higher in long yields following adverse fiscal prints or an OBR shock.
• Buy 12–18 month GBPUSD put options (target 5–10% move) sized 0.5–1% portfolio to hedge sterling depreciation risk if Budget measures or OBR updates signal higher borrowing; set strike ~5% OTM to control premium.
• Reduce exposure to UK-listed education and youth-focused consumer names by 50% within 3 months; redeploy proceeds into healthcare staffing/tech stocks or REITs after confirming policy catalysts (next Budget or National Care Service announcements within 60 days).